BioNTech’s stock closed the week at €79.85, hovering just below its 50-day moving average of €80.81 — a technical threshold the shares have failed to reclaim sustainably. The RSI of 53.9 points to a neutral posture, but the bigger story is a company wedged between a departing founding team and the regulatory inflection point that is supposed to define its post-Covid identity. Vom 52-week high of €105.80, the equity sits almost 25% lower, a discount that reflects both the promise of oncology and the weight of structural uncertainty.
The most concrete catalyst on the horizon is the planned US Biologics Licence Application for Trastuzumab Pamirtecan, an antibody-drug conjugate targeting advanced endometrial cancer. BioNTech and partner DualityBio aim to file in 2026, pending FDA feedback. In China, regulators are already reviewing the drug. The clinical foundation comes from a phase 2 study of 145 patients: the overall response rate reached nearly 48%, while the confirmed objective response rate stood at around 49%. For patients with high HER2 expression that figure climbed to roughly 73%, and median progression-free survival exceeded eight months. The drug’s ability to show activity even at low HER2 levels — a population without approved HER2-directed options — adds an extra layer of differentiation.
But the pipeline does not stop there. The second half of 2026 is expected to deliver seven phase 3 readouts. Among them: data for Gotistobart in non-small cell lung cancer (the PRESERVE-003 study), a pivotal readout for BNT113 in head and neck tumors, and interim results from the Pumitamig programme in NSCLC (ROSETTA Lung-02). In total, the company is running more than 25 clinical trials across phases 2 and 3, of which 13 are pivotal. BioNTech plans to launch six additional phase 3 studies in 2026, bringing the late-stage tally to 15.
None of these trials is generating revenue yet, however. First-quarter 2026 sales shrank to €118.1 million from €182.8 million a year earlier, as Covid vaccine income continues to fade. The consequence was a net loss of €531.9 million. Management has stated it does not expect oncology product revenues in 2026, meaning the company is burning cash while it rebuilds its commercial identity. The balance sheet is strong — €16.8 billion in cash and securities at the end of March — but the clock is ticking on the transition from vaccine dependency to a self-sustaining oncology business.
Should investors sell immediately? Or is it worth buying BioNTech?
That transition must be steered by new leadership. Both founders have announced their departure, leaving the supervisory board searching for a CEO and a chief medical officer. No names have been put forward publicly. In addition, a binding agreement to spin off the mRNA platform to the founders’ new venture was supposed to be signed by the end of June 2026. Official confirmation of that deal is still pending, adding another element of corporate suspense.
Leerink Partners downgraded the stock to Market Perform, citing precisely this leadership vacuum at a moment when execution on a complex late-stage pipeline is critical. The risk is asymmetric: disappointing results from even one or two of the upcoming readouts could damage confidence in the entire oncology strategy. The confirmatory phase 3 study for Trastuzumab Pamirtecan — Fern-EC-01 — is still enrolling, so even a successful BLA filing would leave years before commercial sales materialise.
On the bullish side, analysts see a potential re-rating if the data flow stays positive. The average price target stands at €106.55, and 14 analysts recommend buying the stock while five advise holding. The sheer density of catalysts — seven pivotal readouts plus the filing — means each positive result could lift the shares individually, and a cluster of good news could force a more fundamental reassessment.
Chartwise, the immediate battle is around the 50-day line at €80.81. A sustained break above that could open the path toward the 52-week high, while a failure would make the 52-week low of €68.35 a live target again. The next concrete date on the calendar is 4 August, when second-quarter results are due. Investors will be listening for updates on the FDA filing timeline, the CEO search, and the founder spin-off agreement. Until then, the stock looks likely to tread water in the €80–€85 range, waiting for the leadership puzzle and the data deluge to resolve themselves in sequence.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from June 28 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 28.
BioNTech: Buy or sell? Read more here...
